Table 3.

Associations between prediagnosis supplement use and CIMP status by gender

Male-weighted naFemale-weighted n
CIMPb (%)Non-CIMP (%)OR (95% CI)cPCIMP (%)Non-CIMP (%)OR (95% CI)PInteraction P
Prediagnosis multivitaminsd
 Non-user180 (56.3)1,734 (55.1)1.0206 (45.0)965 (42.9)1.0
 Former user41 (12.9)638 (20.4)0.63 (0.44–0.91)0.0178 (17.0)489 (21.7)0.70 (0.52–0.96)0.03
 User99 (30.9)764 (24.4)1.18 (0.90–1.55)0.24174 (38.1)795 (35.4)0.80 (0.62–1.03)0.080.11 (2)
 Missing746741
Prediagnosis calciumd
 Non-user291 (91.4)2,826 (89.9)1.0242 (53.3)1,277 (57.5)1.0
 Former user10 (3.1)152 (4.8)0.75 (0.38–1.47)0.4064 (14.0)381 (17.2)1.04 (0.74–1.45)0.83
 User17 (5.5)165 (5.2)0.91 (0.53–1.54)0.71149 (32.8)564 (25.4)1.22 (0.95–1.58)0.130.49 (2)
 Missing830968
Prediagnosis NSAIDse
 Non-user105 (34.3)1,748 (56.2)1.0227 (52.0)1,230 (54.9)1.0
 Former user74 (24.1)607 (19.5)1.75 (1.27–2.42)0.000784 (19.3)567 (25.3)0.75 (0.56–1.01)0.06
 User127 (41.6)753 (24.2)2.30 (1.72–3.07)0.0001125 (28.7)445 (19.8)1.40 (1.07–1.83)0.020.0008 (2)
 Missing21632847
HRTf
 Non-user216 (49.5)1,263 (55.9)1.0
 User220 (50.5)996 (44.1)1.17 (0.93–1.47)0.17
2830
  • aAs defined in the text, the sampling weights are the inverse of the sampling fraction which corrected for the oversampling of case probands by age, race, and family history.

  • bDefined as a PMR ≥ 10 for at least 3 of 5 genes: CACNA1G, IGF2, NEUROG1, RUNX3, and SOCS1.

  • cORs and 95% confidence limits estimated using logistic regression and controlling for age (≤50, 51–69, ≥70 years) and tumor site.

  • dUsers were those that answered “yes” to the question “have you ever used [supplement] at least 2 times a week for more than a month” and indicated that they were taking that supplement 1 year before CRC diagnosis. Former users include an unknown number of subjects who began using the supplement after colorectal cancer diagnosis.

  • eUsers were defined as NSAID users if they had used either aspirin or ibuprofen and nonusers if they had not used either at least 1 year before colorectal cancer diagnosis. Former users include an unknown number of subjects who began using the supplement after colorectal cancer diagnosis.

  • fAnswered “yes” to the question “have you ever used a pill or patch form of hormone replacement therapy” for any hormone replacement preparation (estrogen only or estrogen + progesterone) for 6 months or longer.